Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. | Profiles RNS

RCMI Coordinating Center (RCMI CC)

Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease.

Burns JC, Best BM, Mejias A, Mahony L, Fixler DE, Jafri HS, Melish ME, Jackson MA, Asmar BI, Lang DJ, Connor JD, Capparelli EV, Keen ML, Mamun K, Keenan GF, Ramilo O. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr. 2008 Dec; 153(6):833-8.

View in: PubMed

authors with profiles

Marian Melish, MD

RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support